Pipeline Proprietary Delivery Technologies

We seek to marry existing medications with innovative delivery methodologies to enhance the clinical profile to the benefit of patients.

Our two proprietary medication delivery technologies, for which we own exclusive worldwide rights, include:

SmartRelief: An innovative active transdermal technology, rapidly delivering medication through the skin.

  • SmartRelief technology—which has potential applications for proteins/peptides, nucleic acids, and small molecules—has significant franchise opportunity.
  • The global transdermal market is forecasted to grow from $21.5 billion to $31.5 billion by 2015.

LAD, or long-acting delivery: A long-acting biodegradable implant offering improved control, consistency and convenience of long-term medication delivery